Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (23115)	2/22/2007 3:32:43 PM
From: J.F.	Read Replies (2) \| Respond to of 23958

GNBT - everyone see this? Jesup & Lamont Initiates Coverage of Generex Biotechnology With "Buy" Rating and Price Target of $3.25 Jesup & Lamont, a New York-based full-service brokerage and investment banking firm, announced today that it has initiated coverage of Generex Biotechnology (NASDAQ: GNBT) with a "Buy" rating and 12-18 month price target of $3.25 per share. Senior Healthcare Analyst Robert M. Wasserman noted that, "Generex has a deep pipeline, an active industry education program (particularly in the worldwide diabetes market), growing product sales, and plenty of financial resources to provide investors with value-producing progress in the near future." can be tough stuff water skiing broke an ankle once in Salem Harbor when I hit a submerged lobster pot...